219 related articles for article (PubMed ID: 21931726)
1. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
Sarfstein R; Bruchim I; Fishman A; Werner H
PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
[TBL] [Abstract][Full Text] [Related]
2. Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat.
Park MY; Kim DR; Eo EY; Lim HJ; Park JS; Cho YJ; Yoon HI; Lee JH; Lee CT
J Gene Med; 2013; 15(3-4):115-22. PubMed ID: 23413016
[TBL] [Abstract][Full Text] [Related]
3. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
4. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.
Attias-Geva Z; Bentov I; Ludwig DL; Fishman A; Bruchim I; Werner H
Eur J Cancer; 2011 Jul; 47(11):1717-26. PubMed ID: 21450456
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
Takai N; Desmond JC; Kumagai T; Gui D; Said JW; Whittaker S; Miyakawa I; Koeffler HP
Clin Cancer Res; 2004 Feb; 10(3):1141-9. PubMed ID: 14871994
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.
Xu J; Sampath D; Lang FF; Prabhu S; Rao G; Fuller GN; Liu Y; Puduvalli VK
J Neurooncol; 2011 Nov; 105(2):241-51. PubMed ID: 21598070
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Kurundkar D; Srivastava RK; Chaudhary SC; Ballestas ME; Kopelovich L; Elmets CA; Athar M
Toxicol Appl Pharmacol; 2013 Jan; 266(2):233-44. PubMed ID: 23147569
[TBL] [Abstract][Full Text] [Related]
9. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
10. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
[TBL] [Abstract][Full Text] [Related]
12. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T; Galimberti F; Erkmen CP; Memoli V; Chinyengetere F; Sempere L; Beumer JH; Anyang BN; Nugent W; Johnstone D; Tsongalis GJ; Kurie JM; Li H; Direnzo J; Guo Y; Freemantle SJ; Dragnev KH; Dmitrovsky E
Mol Cancer Ther; 2013 Aug; 12(8):1545-55. PubMed ID: 23686769
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
[TBL] [Abstract][Full Text] [Related]
14. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Munshi A; Tanaka T; Hobbs ML; Tucker SL; Richon VM; Meyn RE
Mol Cancer Ther; 2006 Aug; 5(8):1967-74. PubMed ID: 16928817
[TBL] [Abstract][Full Text] [Related]
16. Effects of insulin, insulin-like growth factor-I and -II on proliferation and intracellular signaling in endometrial carcinoma cells with different expression levels of insulin receptor isoform A.
Wang CF; Zhang G; Zhao LJ; Li XP; Qi WJ; Wang JL; Wei LH
Chin Med J (Engl); 2013; 126(8):1560-6. PubMed ID: 23595395
[TBL] [Abstract][Full Text] [Related]
17. Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation.
Bergadà L; Yeramian A; Sorolla A; Matias-Guiu X; Dolcet X
PLoS One; 2014; 9(3):e92764. PubMed ID: 24651472
[TBL] [Abstract][Full Text] [Related]
18. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.
Wu JC; Jiang HM; Yang XH; Zheng HC
Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
